Aura Biosciences (NASDAQ:AURA) Hits New 12-Month High - Should You Buy?

Key Points

• Stock momentum: Aura shares hit a new 52-week high (traded up to $9.54, last $8.90) and were up about 6.6%, with a market cap around $571 million.
• The company closed an underwritten public offering raising roughly $299.4 million, providing near-term capital and reducing financing risk, but the deal added about 46.1 million shares plus pre-funded warrants, creating material dilution that could pressure the stock until clinical milestones validate value.
• Operationally, Aura appointed Natalie Holles as CEO and reported accelerated patient screening toward completion of the Phase 3 CoMpass trial, a development that supports execution and upcoming clinical catalysts.

Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report)'s stock price reached a new 52-week high during trading on Wednesday . The stock traded as high as $9.54 and last traded at $8.90, with a volume of 5880551 shares traded. The stock had previously closed at $8.35.

Aura Biosciences News Summary

Here are the key news stories impacting Aura Biosciences this week:

• Positive Sentiment: Aura closed an underwritten public offering that raised roughly $299.4 million gross, providing capital to advance its lead candidate bel‑sar (AU‑011) and other programs — a near‑term liquidity boost that reduces financing risk for upcoming clinical and registration activities. Article Link
• Positive Sentiment: The company appointed Natalie Holles as CEO and reported accelerated patient screening toward Phase 3 CoMpass enrollment completion — management and operational progress that investors typically view as supportive for execution and upcoming clinical catalysts. Article Link
• Neutral Sentiment: When priced, the offering included pre‑funded warrants and a plan to repurchase up to ~6.9M shares from Matrix Capital at $5.64 per share — a technical maneuver that may modestly offset float increases but has mixed implications depending on future warrant exercises. Article Link
• Negative Sentiment: The offering added 46,099,650 shares (including full exercise of the underwriters’ option) plus pre‑funded warrants, which materially dilutes existing shareholders and can pressure the stock until clinical milestones validate value per share. Article Link
• Negative Sentiment: An analyst note flagged weaker near‑term earnings expectations for Aura, which may temper sentiment until the company demonstrates trial outcomes or revenue progress. Article Link

Wall Street Analysts Forecast Growth

Several research firms have issued reports on AURA. HC Wainwright lifted their price objective on Aura Biosciences from $22.00 to $24.00 and gave the stock a "buy" rating in a report on Wednesday, April 29th. Weiss Ratings reissued a "sell (d-)" rating on shares of Aura Biosciences in a research report on Friday, March 27th. Finally, Wall Street Zen upgraded shares of Aura Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday, April 4th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Aura Biosciences currently has a consensus rating of "Hold" and a consensus price target of $21.50.

Aura Biosciences Stock Up 6.6%

The firm has a market capitalization of $571.38 million, a price-to-earnings ratio of -4.97 and a beta of 0.37. The stock has a 50 day moving average of $6.56 and a 200 day moving average of $6.01.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last announced its quarterly earnings data on Monday, March 30th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.06. Analysts predict that Aura Biosciences, Inc. will post -1.63 earnings per share for the current year.

Insider Buying and Selling at Aura Biosciences

In related news, insider Los Pinos Elisabet De sold 47,648 shares of the firm's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $5.06, for a total transaction of $241,098.88. Following the transaction, the insider directly owned 409,815 shares in the company, valued at $2,073,663.90. This trade represents a 10.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CTO Mark Plavsic sold 15,890 shares of the business's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $5.05, for a total transaction of $80,244.50. Following the sale, the chief technology officer owned 181,397 shares of the company's stock, valued at approximately $916,054.85. The trade was a 8.05% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 116,305 shares of company stock worth $611,230. 6.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Aura Biosciences

A number of institutional investors have recently modified their holdings of AURA. Tower Research Capital LLC TRC lifted its holdings in Aura Biosciences by 49.3% in the second quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company's stock worth $40,000 after acquiring an additional 2,104 shares during the last quarter. ProShare Advisors LLC bought a new position in shares of Aura Biosciences during the fourth quarter valued at approximately $59,000. Water Island Capital LLC acquired a new stake in shares of Aura Biosciences during the 3rd quarter worth approximately $64,000. 49 Wealth Management LLC acquired a new stake in shares of Aura Biosciences during the 3rd quarter worth approximately $66,000. Finally, Invesco Ltd. bought a new stake in shares of Aura Biosciences in the 2nd quarter worth approximately $76,000. Institutional investors own 96.75% of the company's stock.

Aura Biosciences Company Profile

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company's platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.